3 unknown, 1 recruiting. 2 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow CAEBV: new trials by email Literature Review of CAEBV trials Research Report on CAEBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Combined With Selinexor for CAEBVD golidocitinib, Selinexor (combination therapy) - Lymphohistiocytosis, EBV | Phase 2 / Phase 3 | Recruiting | Beijing Friendship Hospital | 28 | 2026-01-01 | 2026-01-27 |
| Selinexol Combined With Dexamethasone in the Treatment of CAEBV Selinexol and Dexamethasone - CAEBV | Phase 3 | Unknown | Beijing Friendship Hospital | 6 | 2022-05-01 | 2022-04-26 |
| Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV low-dose CD20 monoclonal antibody injection - PTLD, CAEBV | Not applicable | Unknown | Beijing Friendship Hospital | 20 | 2021-06-01 | 2022-02-28 |
| Sintilimab and Lenalidomide as a Treatment for CAEBV Sintilimab and lenalidomide, Sintilimab placebo and lenalidomide placebo - CAEBV | Phase 2 | Unknown | Zhao Wang | 51 | 2020-08-01 | 2020-08-19 |
Combined Modality Therapy (1) · Dexamethasone (1) · Lenalidomide (1) · selinexor (1) · sintilimab (1)
Beijing Friendship Hospital (3) · Zhao Wang (1)
China (4)
Yan Cui (1)